Peroxisome proliferator-activated receptor (PPAR) beta/delta : a new potential therapeutic target for the treatment of metabolic syndrome
Metabolic syndrome is defined as the clustering of multiple metabolic abnormalities, including abdominal obesity, dyslipidemia (high serum triglycerides and low serum HDL-cholesterol levels), glucose intolerance and hypertension. The pathophysiology underlying metabolic syndrome involves a complex interaction of crucial factors, but two of these, insulin resistance and obesity (especially visceral obesity), play a major role. The nuclear receptors Peroxisome Proliferator-Activated Receptors (PPAR)alpha and PPARgamma are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively. Evidence is now emerging that the PPARbeta/delta; isotype is a potential pharmacological target for the treatment of disorders associated with metabolic syndrome. PPARbeta/delta; activation increases lipid catabolism in skeletal muscle, heart and adipose tissue and improves the serum lipid profile and insulin sensitivity in several animal models. In addition, PPARbeta/delta; ligands prevent weight gain and suppress macrophage-derived inflammation. These data are promising and indicate that PPARbeta/delta; ligands may become a therapeutic option for the treatment of metabolic syndrome. However, clinical trials in humans assessing the efficacy and safety of these drugs should confirm these promising perspectives in the treatment of the metabolic syndrome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Current molecular pharmacology - 2(2009), 1 vom: 15. Jan., Seite 46-55 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coll, Teresa [VerfasserIn] |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 02.03.2010 Date Revised 11.11.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM193859572 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM193859572 | ||
| 003 | DE-627 | ||
| 005 | 20231223195540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0646.xml |
| 035 | |a (DE-627)NLM193859572 | ||
| 035 | |a (NLM)20021445 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coll, Teresa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Peroxisome proliferator-activated receptor (PPAR) beta/delta |b a new potential therapeutic target for the treatment of metabolic syndrome |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.03.2010 | ||
| 500 | |a Date Revised 11.11.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Metabolic syndrome is defined as the clustering of multiple metabolic abnormalities, including abdominal obesity, dyslipidemia (high serum triglycerides and low serum HDL-cholesterol levels), glucose intolerance and hypertension. The pathophysiology underlying metabolic syndrome involves a complex interaction of crucial factors, but two of these, insulin resistance and obesity (especially visceral obesity), play a major role. The nuclear receptors Peroxisome Proliferator-Activated Receptors (PPAR)alpha and PPARgamma are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively. Evidence is now emerging that the PPARbeta/delta; isotype is a potential pharmacological target for the treatment of disorders associated with metabolic syndrome. PPARbeta/delta; activation increases lipid catabolism in skeletal muscle, heart and adipose tissue and improves the serum lipid profile and insulin sensitivity in several animal models. In addition, PPARbeta/delta; ligands prevent weight gain and suppress macrophage-derived inflammation. These data are promising and indicate that PPARbeta/delta; ligands may become a therapeutic option for the treatment of metabolic syndrome. However, clinical trials in humans assessing the efficacy and safety of these drugs should confirm these promising perspectives in the treatment of the metabolic syndrome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Lipoproteins |2 NLM | |
| 650 | 7 | |a PPAR delta |2 NLM | |
| 650 | 7 | |a PPAR-beta |2 NLM | |
| 700 | 1 | |a Rodrïguez-Calvo, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Barroso, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano, Lucïa |e verfasserin |4 aut | |
| 700 | 1 | |a Eyre, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Palomer, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Vázquez-Carrera, Manuel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current molecular pharmacology |d 2008 |g 2(2009), 1 vom: 15. Jan., Seite 46-55 |w (DE-627)NLM185149499 |x 1874-4702 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2009 |g number:1 |g day:15 |g month:01 |g pages:46-55 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2009 |e 1 |b 15 |c 01 |h 46-55 | ||